A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

Mounjaro has been approved for both type 2 diabetes and weight loss; however, access will be limited by strict eligibility ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...